Is 3'-deoxy-3'-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue SUPPL. 13, 2006, Pages

  Reske, Sven N ^a   Deisenhofer, Sandra ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Clinical studies; Fluorothymidine; Metabolism; Monitoring; Treatment response

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IBRITUMOMAB TIUXETAN; METHOTREXATE; RADIOISOTOPE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER THERAPY; CELL PROLIFERATION; DRUG METABOLISM; FIBROSARCOMA; FOLLICULAR LYMPHOMA; HUMAN; IMAGING SYSTEM; MONITORING; NONHUMAN; PROSTATE TUMOR; SCID MOUSE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR MODEL; TUMOR XENOGRAFT; CELL CYCLE REGULATION; CELL CYCLE S PHASE; DISEASE MARKER; ISOTOPE LABELING; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 33746516137     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0134-2     Document Type: Article

References (55)

1. Hricak H, Akin O, Bradbury MS, Lieberman L, Schwartz LH, Larson SM. Advanced imaging methods: functional and metabolic imaging. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 7 ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 589-720
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
3. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-23
4. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-93
5. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 2000;97:9226-33
6. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-30
7. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530-41
8. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496-507
9. Shields AF, Mankoff D, Graham MM, Zheng M, Kozawa SM, Link JM, et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 1996;37:290-6
10. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, et al. Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine. J Nucl Med 1994;35:1407-17
11. 124I] iododeoxyuridine. Cancer Res 2000;60:624-35
12. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6
13. Plagemann PG, Richey DP, Zylka JM, Erbe J. Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment. Exp Cell Res 1974;83:303-10
14. Hopwood LE, Dewey WC, Hejny W. Transport of thymidine during the cell cycle in mitotically synchronized CHO cells. Exp Cell Res 1975;96:425-9
15. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89
16. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8
17. Eriksson S, Munch-Petersen B, Johansson K, Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 2002;59:1327-46
18. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991;266:9032-8
19. Wang J, Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-Iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxity. Antimicrob Agents Chemother 1996;40:1555-7
20. Kornberg A, Baker TA. Biosynthesis in DNA precursors. DNA replication. 2nd ed. New York: W.H. Freeman; 1992. p. 53-100
21. Skladanowski AC, Hoffmann C, Krass J, Jastorff B, Makarewicz W. Structure-activity relationship of cytoplasmic 5′-nucleotidase substrate sites. Biochem J 1996;314 Pt 3:1001-7
22. Garvey EP, Lowen GT, Almond MR. Nucleotide and nucleoside analogues as inhibitors of cytosolic 5′-nucleotidase I from heart. Biochemistry 1998;37:9043-51
23. Gazziola C, Ferraro P, Moras M, Reichard P, Bianchi V. Cytosolic high K(m) 5′-nucleotidase and 5′(3′)-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism. J Biol Chem 2001;276:6185-90
24. Mansson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 2003;65:237-47
25. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 2004;31:829-37
26. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′- deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992;36:808-18
27. Sundseth R, Joyner S, Moore J, Dornsife R, Dev I. The antihuman immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother 1996;40:331-5
28. Langen P, Etzold G, Hintsche R, Kowollik G. 3′-Deoxy-3′- fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol Med Ger 1969;23:759-66
29. Matthes E, Lehmann C, Scholz D, Rosenthal HA, Langen P. Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidine. Biochem Biophys Res Commun 1988;153:825-31
30. Stryer L. Biochemistry. 4 ed. New York: W.H. Freeman; 1995
31. Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 2000;87:189-98
32. Caligo MA, Cipollini G, Fiore L, Calvo S, Basolo F, Collecchi P, et al. NM23 gene expression correlates with cell growth rate and S-phase. Int J Cancer 1995;60:837-42
33. Lacombe M-L, Milon L, Munier A. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000;32:247-58
34. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659-72
35. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9
36. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-70
37. 18F-FDG. J Nucl Med 2003;44:1426-31
38. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23
39. 18F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 2004;45:1677-82
40. 18F-FDG PET. J Nucl Med 2004;45:226-31
41. 18F-FDG PET in esophageal cancer. J Nucl Med 2005;46:400-4
42. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4
43. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82
44. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006;129:393-401
45. 18F-FDG. J Nucl Med 2005;46:945-52
46. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31:720-4
47. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36-42
48. Jakob C, Liersch T, Meyer W, Baretton GB, Hausler P, Schwabe W, et al. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 2005;29:1304-9
49. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro2′-deoxyuridine. World J Gastroenterol 2004;10:172-6
50. Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol 2002;29:258-63
51. 18F-fluorothymidine PET. J Nucl Med 2005;46:114-20
52. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754-8
53. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10
54. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8
55. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2005;45:519-25